GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific comm...
CEC Capital advises Zhongkexinyang on 100-million-yuan private financing round
GEMPHARMATECH released its performance for the first three quarters, with a net profit attributable to the parent company of 110 million yuan, a year-on-year increase of 11.9%
GEMPHARMATECH: Net profit in the first half of 2025 was 70.9055 million yuan, a year-on-year decrease of 7.12%
The CRO sector rose, with JOINN up 8.94%, GEMPHARMATECH up 7.3%, Bide up 6.7%, and TIGERMED, Chemexpress, and Sun-Novo all rising over 5%
Overview of the lifting of restrictions on A-shares by Zhitong | April 25
GemPharmatech opens new biotech hub in San Diego, boosting research capabilities with lab and vivarium.